Electromed, Inc. ELMD R2K
Healthcare · Medical Devices · United States
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
READ MORE ›$37.72
+86.73% 1Y
Market & Price
Market Cap
$312.32M
Current Price
$37.72
High / Low (52W)
$39.29 / $18.12
Beta
0.39
Valuation
Stock P/E
32.24
Industry PE
23.65
Forward P/E
61.84
PEG Ratio
0.35
Book Value
$5.49
Price to Book
6.87
P/S
4.35
EV/EBITDA
20.36
Dividend Yield
-
Profitability & Returns
ROCE
22.29%
ROE
21.70%
ROA
14.86%
Profit Margin
14.08%
Op Margin
20.28%
EPS (Latest Qtr)
$0.35
EPS (TTM)
$1.17
Balance Sheet & Liquidity
Debt/Equity
0.17
Quick Ratio
4.53
Current Ratio
4.91
Debt
$81.00K
Total Assets
$53.80M
Current Assets
$45.08M
Working Capital
$34.61M
Ownership
Promoter Holding
21.44%
Chg in Prom Hold
-
FII / Inst Holding
59.20%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$295.42M
Total Revenue (TTM)
$71.75M
EBITDA
$14.51M
Free Cash Flow
$8.32M
Operating Cash Flow
$10.53M
Shares Outstanding
8.28M
Gross Margin
78.44%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
15.39%
Profit 5Y
48.43%
Revenue (YoY)
18.40%
Earnings (YoY)
66.70%
PROS
- Strong return on equity of 21.7%.
- Healthy ROCE of 22.3%.
- Compounding revenue at 15.4% over 5 years.
- Profit CAGR of 48.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELMD Electromed, Inc. R2K | 37.72 | 32.24 | $312.32M | - | 22.29% | 21.70% | 15.39% | 48.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 6.30M | 6.96M | 7.17M | 7.28M | 8.01M | 7.41M | 8.30M | 8.55M | 8.74M | 8.00M | 9.50M | 8.79M | 10.00M | 10.25M | 10.14M | 10.66M | 11.73M | 12.07M | 12.32M | 13.69M | 13.87M | 14.67M | 16.25M | 15.68M | 17.39M | 16.89M | 18.90M | 18.57M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.46M | 3.77M | 3.69M | 4.08M | 3.93M |
| Gross Profit | 2.36M | 2.52M | 2.52M | 3.29M | 3.40M | 3.16M | 3.86M | 4.90M | 4.63M | 4.33M | 4.93M | 5.31M | 4.69M | 5.40M | 5.51M | 5.54M | 6.06M | 5.57M | 6.34M | 6.68M | 6.59M | 6.15M | 7.53M | 6.70M | 7.70M | 7.88M | 7.74M | 8.33M | 8.68M | 9.06M | 9.50M | 10.54M | 10.38M | 11.49M | 12.63M | 12.23M | 13.62M | 13.20M | 14.82M | 14.64M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.09M | 10.58M | 10.53M | 11.20M | 10.88M |
| Operating Income | -577.20K | -308.79K | -217.06K | 397.98K | 447.39K | 57.58K | 585.17K | 1.25M | 735.69K | 288.88K | 729.46K | 1.04M | 99.15K | 770.65K | 577.82K | 201.71K | 675.00K | 464.55K | 1.35M | 1.57M | 913.10K | 663.00K | 1.58M | 243.00K | 538.00K | 1.08M | 863.00K | 44.00K | 1.27M | 1.20M | 142.00K | 2.26M | 1.84M | 1.94M | 2.54M | 2.14M | 3.04M | 2.67M | 3.62M | 3.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.42M | 3.44M | 2.93M | 3.88M | 4.05M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.28M | 3.17M | 2.80M | 3.73M | 3.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 391.00K | 971.00K | 668.00K | 968.00K | 863.00K |
| Net Income | -335.40K | -239.26K | -1.00M | 377.53K | 422.71K | 37.23K | 340.96K | 1.07M | 466.62K | 191.17K | 443.86K | 647.95K | 80.95K | 419.76K | 376.49K | 157.16K | 380.52K | 352.93K | 1.01M | 1.19M | 653.27K | 535.00K | 1.20M | 224.00K | 439.00K | 838.00K | 645.00K | 81.00K | 977.00K | 1.07M | 155.00K | 1.67M | 1.49M | 1.47M | 1.97M | 1.89M | 2.20M | 2.14M | 2.76M | 3.00M |
| Diluted EPS | - | -0.03 | -0.12 | 0.05 | 0.05 | 0.00 | 0.04 | 0.13 | 0.06 | 0.02 | 0.05 | 0.08 | 0.01 | 0.05 | 0.04 | 0.02 | 0.04 | 0.04 | 0.12 | 0.14 | 0.07 | 0.06 | 0.13 | 0.03 | 0.05 | 0.10 | 0.07 | 0.01 | 0.11 | 0.12 | 0.02 | 0.19 | 0.17 | 0.16 | 0.22 | 0.21 | 0.25 | 0.25 | 0.32 | 0.35 |
| R&D Expense | 209.11K | 92.73K | 103.17K | 75.27K | 83.64K | 78.29K | 41.54K | 57.09K | 84.41K | 350.84K | 100.80K | 80.61K | 70.66K | 56.79K | 42.66K | 68.19K | 237.84K | 170.76K | 98.94K | 143.48K | 391.96K | 481.00K | 507.00K | 407.00K | 376.00K | 329.00K | 336.00K | 298.00K | 154.00K | 166.00K | 206.00K | 107.00K | 167.00K | 166.00K | 251.00K | 277.00K | - | 241.00K | 384.00K | 361.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 28.31M | 31.30M | 32.47M | - | 41.66M | 48.07M | 54.72M | 64.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 10.22M | 11.55M | 12.99M | 14.03M |
| Gross Profit | 13.78M | 14.15M | 10.45M | 10.63M | 13.60M | 17.88M | 20.57M | 21.77M | 23.85M | 25.20M | - | 31.44M | 36.52M | 41.73M | 49.97M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 28.47M | 32.51M | 35.15M | 40.31M |
| Operating Income | 1.87M | 606.34K | -1.83M | -740.59K | 1.31M | 3.11M | 3.57M | 2.71M | 2.83M | 5.12M | - | 2.97M | 4.01M | 6.58M | 9.66M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 3.60M | 4.62M | 7.42M | 10.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 4.09M | 7.04M | 10.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 692.00K | 920.00K | 1.89M | 2.75M |
| Net Income | 1.06M | 186.61K | -1.33M | -1.29M | 1.09M | 2.21M | 2.23M | 1.83M | 1.98M | 4.16M | - | 2.31M | 3.17M | 5.15M | 7.54M |
| Diluted EPS | 0.13 | 0.02 | - | -0.16 | 0.13 | 0.27 | 0.26 | 0.21 | 0.23 | 0.47 | - | 0.26 | 0.36 | 0.58 | 0.85 |
| R&D Expense | 1.03M | 920.77K | 603.38K | 466.06K | 315.65K | 380.39K | 596.88K | 251.44K | 583.31K | 1.05M | 1.72M | 1.36M | 916.00K | 656.00K | 996.00K |
Compounded Sales Growth
| 5 Years: | 15.39% |
| 1 Year: | 18.40% |
Compounded Profit Growth
| 5 Years: | 48.43% |
| 1 Year: | 66.70% |
Stock Price Performance
| 1 Year: | +86.73% |
| 6 Months: | +36.27% |
| 3 Months: | +59.16% |
| 1 Month: | +50.28% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 20.87M | 20.92M | 17.56M | 15.79M | 17.41M | 20.58M | 23.06M | 27.39M | 29.40M | 33.24M | - | 41.36M | 45.81M | 52.23M | 53.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 34.54M | 37.79M | 44.17M | 45.08M |
| Cash & Equivalents | 610.73K | 4.09M | 1.70M | 503.56K | 1.50M | 3.60M | - | - | - | - | 10.48M | - | 8.15M | 7.37M | 16.08M | 15.29M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 3.18M | 4.22M | 3.71M | 3.30M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 21.05M | 24.13M | 23.33M | 24.66M |
| Total Liabilities | - | 6.16M | 5.84M | 3.63M | 3.07M | 3.48M | 4.22M | 3.99M | 4.74M | 3.67M | 3.00M | - | 7.19M | 8.14M | 7.69M | 10.59M |
| Current Liabilities | - | 4.41M | 4.17M | 2.19M | 1.82M | 2.28M | 3.07M | 2.90M | 4.80M | 3.65M | 2.99M | - | 7.15M | 8.05M | 7.68M | 10.47M |
| Long Term Debt | - | 1.58M | 1.39M | 1.33M | 1.25M | 1.20M | 1.15M | 1.10M | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | - | 14.71M | 15.08M | 13.93M | 12.72M | 13.92M | 16.36M | 19.83M | 22.58M | 25.73M | 30.25M | - | 34.17M | 37.67M | 44.55M | 43.21M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 8.48M | 8.56M | 8.64M | 8.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.42M | -1.17M | - | - | - | 2.17M | 1.19M | 2.44M | 2.59M | 4.20M | - | -686.00K | 1.31M | 9.07M | 11.39M |
| Investing Cash Flow | -1.11M | -848.75K | - | - | - | -579.52K | -687.15K | -571.78K | -1.39M | -977.00K | - | -1.52M | -1.72M | -395.00K | -306.00K |
| Financing Cash Flow | 6.01M | -368.78K | - | - | -61.17K | -62.27K | -53.62K | 11.71K | -851.15K | -548.00K | - | -1.52M | -380.00K | 36.00K | -11.88M |
| Capital Expenditure | -466.31K | -791.55K | -1.02M | -895.18K | -523.18K | -534.94K | -618.76K | -526.23K | -1.33M | -844.00K | - | -1.52M | -1.72M | -395.00K | -306.00K |
| Free Cash Flow | -1.88M | -1.96M | - | - | - | 1.63M | 572.36K | 1.92M | 1.26M | 3.35M | - | -2.21M | -401.00K | 8.67M | 11.09M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -3.74M | -781.00K | 8.71M | -793.00K |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 1.12M | 1.45M | 153.00K | 275.00K | 10.00M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 76.9% | 76.2% | 77.6% | - | 75.5% | 76.0% | 76.3% | 78.1% |
| Operating Margin % | - | - | - | - | - | - | - | 9.6% | 9.0% | 15.8% | - | 7.1% | 8.3% | 12.0% | 15.1% |
| Net Margin % | - | - | - | - | - | - | - | 6.5% | 6.3% | 12.8% | - | 5.5% | 6.6% | 9.4% | 11.8% |
| ROE % | 7.2% | 1.2% | -9.5% | -10.1% | 7.8% | 13.5% | 11.2% | 8.1% | 7.7% | 13.8% | - | 6.7% | 8.4% | 11.6% | 17.4% |
| ROCE % | 11.4% | 3.6% | -11.9% | -5.3% | 8.7% | 17.8% | 17.7% | 12.0% | 11.0% | 16.9% | - | 8.7% | 10.6% | 14.8% | 22.3% |
Shareholding Pattern
Insiders
21.44%
Institutions
59.20%
Public Float
75.36%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | J.e. Simmons & Co., P.c. | 5.95% | 492.82K | $18.59M |
| 2 | Blackrock Inc. | 5.54% | 458.85K | $17.31M |
| 3 | Vanguard Capital Management LLC | 4.05% | 335.03K | $12.64M |
| 4 | Punch & Associates Investment Management, Inc. | 2.71% | 224.52K | $8.47M |
| 5 | Acadian Asset Management. LLC | 2.69% | 222.75K | $8.40M |
| 6 | Two Sigma Investments, LP | 2.46% | 203.60K | $7.68M |
| 7 | Geode Capital Management, LLC | 2.44% | 201.89K | $7.62M |
| 8 | Dimensional Fund Advisors LP | 2.15% | 178.27K | $6.72M |
| 9 | Hunter Associates Investment Management LLC | 1.82% | 150.80K | $5.69M |
| 10 | Gamco Investors, Inc ET AL | 1.71% | 142.00K | $5.36M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELMD
No recent headlines available.